Imvax Inc. Raises $112 Million in Series C Financing

Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme, Phase 1 research into additional solid tumor indications and build out of the operational capabilities PHILADELPHIA, July 16, 2020 -- (Healthcare Sales & ... Biopharmaceuticals, Oncology, Venture Capital Imvax Inc, neo-antigen immunotherapy, glioblastoma multiforme
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news